Recombinant human G-CSF (rHuG-CSF) is used for hematopoietic progenitor cells (HPC) mobilization and collection. Activation of polymorphonuclear leukocytes (PMN) is present during rHuG-CSF treatment and is associated with endothelial cell dysfunction and hypercoagulation. We evaluated whether PMN activation by rHuG-CSF may alter the blood oxidative status and subsequently affect the vascular cell function. Fourteen healthy individuals received rHuG-CSF for HPC harvesting. Blood was drawn before starting rHuG-CSF (T0), on the last day of rHuG-CSF (T1) and 1 week after stopping rHuG-CSF (T2). Levels of CD11b, myeloperoxidase (MPO), hydroperoxides, nitric oxide (NO), and soluble endothelium (sES), leukocyte (sLS), and platelet (sPS) selectins were measured. During rHuG-CSF, CD11b, MPO and hydroperoxides significantly increased, while NO levels significantly decreased, compared with T0. At T2 all these markers returned to baseline values. Significant increments of all selectins were observed during rHuG-CSF. At T2 sES and sEP significantly decreased back to pre-treatment values, whereas sLS remained significantly high. These data show that rHuG-CSF induces a transient inflammatory status characterized by circulating activated PMN, which release reactive oxygen species and intracellular proteases, promoting the onset of an abnormal oxidative status. This process may modify the hemostatic balance towards a pro-thrombotic state.
Introduction
Granulocyte colony stimulating factor (G-CSF) is a hematopoietic cytokine that stimulates the proliferation and the release of mature granulocytes from the bone marrow into the circulating blood. 1 As a result of its capability to mobilize CD34 þ hematopoietic progenitor cells (HPC) into circulating blood, G-CSF is also used for HPC mobilization and collection for both allogeneic and autologous bone marrow transplantation. 2 In cancer patients receiving hematopoietic growth factors an increased tendency to thrombosis has been described. 3 In healthy donors of HPC, endothelial cell dysfunction and clotting activation have been demonstrated during treatment with rHuG-CSF for hematopoietic progenitor cells harvesting. 4 Specifically, in the circulation, high levels of endothelium activation markers (i.e. thrombomodulin and von Willebrand factor (vWF)), and of markers of hypercoagulability (i.e. prothrombin fragment F1 þ 2, thrombin-antithrombin complex and D-Dimer) were found. This occurred together with a concomitant activation of circulating PMN, as demonstrated by the findings of significant increment of PMN surface CD11b/CD18 expression, PMN cellular elastase content, and in plasma elastase levels. 4 These findings have been interpreted by the possibility that G-CSF not only regulates the numbers of circulating PMN, but also modulates the function of mature and newly developed PMN subsequently released from the bone marrow in response to G-CSF: that is, changes in adherence, movement, phagocytosis, priming and stimulation of the respiratory burst, secretion, and degranulation. [5] [6] [7] [8] Activated PMN release reactive oxygen species and intracellular proteases, which possess several activities on endothelial cells and platelets, and may modify the hemostatic balance towards a pro-thrombotic state. [9] [10] [11] [12] [13] To evaluate whether the activation of PMN function in healthy individuals by G-CSF may actually alter the blood oxidative status and subsequently affect the vascular cell function, the levels of hydroperoxides and nitric oxide together with the levels of circulating soluble endothelium, leukocyte, and platelet selectins were measured in a group of healthy HPC donors treated with G-CSF.
Materials and methods
Fourteen consecutive healthy individuals (10 males and four females; median age: 35 years, range 8-65 years) received recombinant human G-CSF (rHuG-CSF) for HPC mobilization into the peripheral blood and use for allogeneic transplant. 4 Detailed written informed consent was obtained from each donor before starting the procedure. Medical history, physical examination and routine laboratory investigation were normal in all subjects. These subjects were also negative for history of thrombosis and other known risk factors for thrombosis. rHuG-CSF (10 mg/kg/day) was administered subcutaneously for 5-6 consecutive days. The daily dose was administered in two half doses, each administered every 12 h. Leukapheresis was performed on a Cobe Spectre continuous flow cell separator on day 5 or 6 of rHuG-CSF administration (when CD34 þ cells were 40.5%). rHuG-CSF was stopped on the day of leukapheresis.
Blood samples collection
Venous blood was collected into sterile siliconized tube containing trisodium citrate (0.129 mol/l, 1:10 vol/vol). Blood samples were obtained before the first morning injection of rHuG-CSF (T0), on the fifth or the sixth consecutive day of rHuG-CSF administration (T1) and 1 week after leukapheresis and stopping rHuG-CSF (T2). Plasma was obtained by centrifugation of anticoagulated whole blood at 3000 g for 20 min at room temperature and stored in aliquots at À801C until assays.
Routine hematologic assays
White blood cell differential count (WBC), hematocrit, hemoglobin, red blood cell (RBC) and platelet counts were determined by automated methods using an NE800 Analyser (Dasit, Milan, Italy).
PMN activation markers
The expression of CD11b on PMN surface and the plasma levels of myeloperoxidase (MPO) were used as markers of PMN activation. 4, 13 Whole blood was used for the cytofluorimetric evaluation of the expression of CD11b on the surface of PMN. Particularly, 50 ml of blood were incubated with saturating concentration of phycoerythrin (PE)-conjugated mouse anti-human CD11b MoAb (Becton Dickinson, Mountain View, CA, USA) or with an isotype-identical negative control MoAb (IgG2a-PE, Becton Dickinson). Samples were left undisturbed for 30 min in the dark, at room temperature (RT). Then, after red cell lysis, the samples were resuspended in phosphate-buffered saline (PBS) and immediately analyzed by a FACScan flow cytometer (Becton Dickinson). PMN were selectively gated using their forward-and side-scatter properties and 5000 PMN-gated events were measured for each sample. Data acquisition and processing were performed with the Cell Quest software (Becton Dickinson). The results are expressed as mean fluorescence intensity (MFI) units.
Plasma MPO is a marker of PMN azurophil granule content release into the bloodstream.
14 Plasma MPO was measured by using a commercial ELISA kit (Bioxytech MPO, Enzyme Immunoassay; Oxis-International, Portland, OR, USA). Results are expressed in mg/ml.
Oxidative status
The plasma oxidative status was evaluated by measuring the levels of hydroperoxides by the d-ROMs test (Diacron, Grosseto, Italy). This method is based on the ability of transition metals to catalyze, in the presence of peroxides, the formation of free radicals that are trapped by an alchylamine. 10 The alchylamine reacts forming a colored radical detectable at 505 nm through a kinetic reaction. The results are expressed in Carratelli (Carr) units.
Nitric oxide
Plasma levels of nitric oxide (NO) were determined as a measure of nitrate þ nitrite (NO 2 /NO 3 ) metabolites using a commercial ELISA kit (Cayman, Ann Arbor, MI, USA). Results are expressed in nmol/l.
Soluble selectins
As markers of blood cell perturbance, the plasma levels of soluble adhesion molecules of the selectin class, that is, endothelium (sES), leukocyte (sLS) and platelet (sPS) selectin, were determined by using commercially available ELISA kits (R&D Systems Inc., Minneapolis, MN, USA). The results of all selectins are expressed in ng/ml.
Statistical analysis
All results are expressed as a mean7standard error (s.e.) of the mean. Analysis of the differences was performed by MannWhitney U-test. A P-value o0.05 has been considered significant.
Results
Routine hematological parameters Table 1 shows the variations of the healthy donors' hematological parameters at the different times of the study. At baseline (T0), before the start of rHuG-CSF treatment, none of the subjects had hematological abnormalities. Then, all of them responded to rHuG-CSF administration, with a significant increase (Po0.01) in WBC as well as in the PMN count. WBC and PMN were back to the basal values 1 week after HPC collection and rHuG-CSF discontinuation (T2). No significant modifications occurred to the other hematological parameters during treatment, except for the median platelet count, which tended to decrease on T1, at the peak of rHuG-CSF-induced leukocytosis. After apheresis (T2), this reduction became statistically significant. Also at this time, the hematocrit, hemoglobin, and RBC counts were slightly, but significantly decreased compared with the baseline.
CD11b and MPO
A cytofluorimetric analysis of the b2 integrin CD11b activation marker expressed by PMN was performed to confirm, in this group of healthy donors, whether the administration of G-CSF induces an activation status in these cells. Figure 1a shows that a significant increase in CD11b levels (Po0.0001) occurred on PMN surface during G-CSF administration (315723 MFI) Blood oxidative status induced by G-CSF G Cella et al compared to baseline levels (127711 MFI). No significant differences were observed in CD11b surface levels of blood samples collected after G-CSF discontinuation (166719 MFI) and at baseline. In parallel to the CD11b increment on PMN surface, a significant increase in MPO plasma concentrations in the circulation of the donors was observed in T1 compared with baseline levels (T0 vs T1: 54.179.8 vs 236729 mg/l, Po0.01). At T2 the levels of MPO significantly declined to baseline values (61711 mg/l) (Figure 1b) .
Oxidative status
The plasma concentration of hydroperoxides significantly rose during G-CSF administration compared with baseline levels (T0 vs T1: 167716 vs 198716 carr units; Po0.01). This marker tended to be elevated at T2 compared to T0, but the difference was not statistically significant (Figure 2a ).
Nitric oxide
At T1, after 5 days of rHuG-CSF treatment, the levels of NO 2 / NO 3 were significantly decreased in the plasma of healthy donors as compared to pre-treatment values (T0 vs T1: 8.1571.54 vs 5.5570.98 nmol/ml, Po0.05). One week after stopping rhG-CSF the levels of NO 2 /NO 3 rose towards baseline levels (T2: 6.273.1 nmol/ml) (Figure 2b ).
Plasma selectins
At T0, the circulating levels of each selectins were within the normal range values. As shown in Figure 3 , a significant increment of all the three selectins was observed during rHuG-CSF treatment (T0 vs T1: sE-selectin: 13.475.6 vs 23.377.2 ng/ml, Po0.01; sL-selectin: 11777253 vs 14867313 ng/ml, Po0.01; sP-selectin: 52.1713.1 vs 73.1722.1 ng/ml, Po0.01). At T2, one week after leukapheresis and stopping rHuG-CSF, sE-selectin and sP-selectin significantly decreased back to pre-treatment values (sE-selectin: 17.775.9 ng/ml, Po0.05; sP-selectin: 52.5713.1 ng/ml, Po0.05), whereas sL-selectin remained at significantly higher levels compared to T0 (15947298 ng/ml, Po0.05).
Discussion
Endothelial cell dysfunction and blood clotting activation are present in healthy donors during treatment with rHuG-CSF for hematopoietic progenitor cells harvesting. In the circulation of these individuals, high levels of thrombomodulin, vWF, prothrombin fragment F1 þ 2, thrombin-antithrombin complex and D-dimer have been demonstrated in association to the occurrence of activated PMN (i.e. increased surface CD11b expression, PMN cellular elastase content, and plasma elastase levels). [4] [5] [6] [7] In the present study we found that, in healthy donors, the increase in PMN activation markers (as evaluated by the increase in CD11b and MPO markers) occurred with a concomitant reduction of plasma NO levels and an increase in the oxidative status (i.e. plasma hydroperoxides), and plasma selectins levels during rHuG-CSF administration.
NO, produced by vascular endothelium, is a powerful vasodilator and inhibitor of platelet adhesion and aggregation, leukocytes adhesion/infiltration, and proliferation of vascular smooth muscle cells. 12 It is formed in endothelial cells from its T1  T2  T0  T1  T2  T0  T1  T2 * * * * Figure 3 Plasma levels of E-, L-and P-selectins in healthy HPC donors before (T0), during (T1) and one week after leukapheresis and stopping (T2) rHuG-CSF administration. The results are mean7s.e. *Po0.05 vs T0.
precursor L-arginine via the enzymatic action of endothelial NO synthase. Defect in NO production or activity has been proposed as a major mechanism of endothelial dysfunction that leads to events or actions that promote atherosclerosis and thrombosis.
The reduced plasma levels of this endothelial-derived compound observed in our study subjects may be due to an inhibitory effect of G-CSF or to the release of reactive oxygen species and intracellular proteases (i.e. elastase and MPO) that possess several activities on endothelial cells. It has been recently shown that MPO modulates the vascular signaling and vasodilatory functions of NO during acute inflammation. 14 Altered vascular responsiveness was due to catalytic consumption of NO by substrate radicals generated by MPO. In keeping with previous data of PMN elastase, 4 both hydroperoxides and MPO significantly increased during rHuG-CSF administration and this could explain the reduced level of NO. Moreover, oxidative stress appears to be associated with an increased production of oxygen free radicals, which alters the natural antioxidant defense mechanism, present in most tissues. In fact, in patients with angiographic restenosis a significant increase in lipid peroxidation accompanied by a reduction in the stable end products of NO in plasma is observed several months after coronary angioplasty. 15 We hypothesized that during G-CSF administration a significant alteration of the endothelium might occur in association with abnormal oxidative stress. The occurrence of endothelial cell activation is supported by our results on plasma soluble selectin measurements, showing an increase in the plasma levels of the selectins of endothelial origin (i.e. E-and P-selectin).
Specifically, we found that the plasma levels of three selectins, that is, sE-, sL-and sP-selectins, increased significantly at the end of rHuG-CSF administration before leukapheresis. At 1 week after leukapheresis and stopping rHuG-CSF, sE-and sP-selectins decreased back to pre-treatment values, whereas sL-selectin did not. Our observation is partially in keeping with the findings by Ohsaka et al., 11 which showed significant increased levels of sE-and sL-but not of sP-selectin after G-CSF administration. It is possible that this discrepancy could be due to the small number of healthy subjects they studied. Increased levels of sP-selectin could be due to endothelial cell activation and/or to the shedding of this molecule from platelet surface. Indeed P-selectin is present on both activated platelets and endothelial cells. 16, 17 We exclude that this increment may be secondary to an increase in platelet count, as platelet number was rather decreased by G-CSF administration in these patients. PMN intracellular proteases induce potent platelet activation 18 they could directly proteolyze P-selectin from platelet cell surface as well as from endothelial cells.
It has been shown by Ohsaka et al. 11 that G-CSF downregulates the expression of L-selectin on the cell surface of neutrophils both 'in vitro' and 'in vivo'. L-selectin on the surface of neutrophils is involved in the initial capture and subsequent rolling of leukocytes along the endothelium in conjunction with E-selectin and P-selectin. L-selectin is shed into the serum from leucocytes in response to activation. 19 Accordingly, in our subjects we found a significant elevation in the plasma levels of sL-selectin. This increment may be due to the proteolytic shedding of this molecule from the cell membrane of activated neutrophils associated to the increase in circulating number of neutrophils.
From our experience, G-CSF administration induces an inflammatory process with endothelial cell activation. This effect is due to the release from activated PMN, of reactive oxygen species and intracellular proteases with an abnormal oxidative stress that may modify the hemostatic balance towards a pro-thrombotic state.
None of the study subjects experienced thrombotic events during G-CSF administration, suggesting that the transient, although significant, alteration in the markers reported here does not indicate a real thrombotic risk for healthy persons. Possibly, in healthy subjects compensatory hemostatic mechanisms prevent the onset of thrombotic events, although cases of unstable angina have been reported in healthy donors of progenitor cells given G-CSF. 20, 21 However, it is likely that our findings of increased pro-inflammatory and pro-thrombotic effects in individuals given G-CSF may be of particular interest in subjects with underlying diseases. Indeed, serious thrombotic adverse events (i.e., one non-ST elevation miocardial infarction and one fatal miocardial infarction) occurred in a series of subjects with advanced coronary artery disease and recurrent ischemia receiving rHuG-CSF treatment to mobilize progenitor stem cells. 22 In addition, cases of acute arterial and venous thrombosis have been reported in patients with cancer, 3, 23 although, in malignancy, a number of other variables (i.e. tumor cell procoagulants, cytokines, chemotherapy, etc.) can influence blood coagulation and contribute to the occurrence of thrombotic complications during G-CSF.
It is important to note that an elevated white blood cell count and the neutrophil activation status also contribute to the increased thrombotic risk in human conditions not related to G-CSF administration. Indeed, persistent accumulation of neutrophils, together with increased blood levels of G-CSF, lectins and hydroperoxides, are physiological components of the acute phase response in humans and predispose to arterial and venous thrombosis as well as to disseminated intravascular coagulation in severe sepsis. In addition, activated neutrophils may play a relevant role in the thrombophilic state of patients with chronic myeloproliferative disorders. 13, 24 In conclusion, a careful clinical monitoring for thrombosis during G-CSF may be advisable in otherwise healthy donors of hematopoietic stem cells, who carry known thrombotic risk factors.
